Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | SCD | O00767 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694046 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL5591384 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL7271736 | 0.82 | KDM4E (0.52) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL3331253 | 0.81 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL5591276 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL5590969 | 0.77 | ALDH1A1 (0.97) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| Hydrochloric Acid SCHEMBL5591487 | 0.77 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL26086680 | 0.76 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL30104615 | 0.76 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDPKMRAB9A | |
| SCHEMBL15245183 | 0.76 | KDM4E (0.62) | ALDH1A1KDM4EHPGDPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007034277-A1 | ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-10933049-B2 | Mobilizing agents and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-02 | — | — | US | disclosed |
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-07-05 | — | — | US | disclosed |
| EP-3302710-A1 | MOBILIZING AGENTS AND USES THEREFOR | The University of Queensland (AU) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191811-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-12-08 | — | — | WO | disclosed |
| WO-2007034277-A1 | ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | C3AR1, CSF3R, C5AR1 | ALDH1A1 2492/4885KDM4E 4833/4885HPGD 1396/4885 |
| US-10933049-B2 | Mobilizing agents and uses therefor | C3AR1, CSF3R, C5AR1 | ALDH1A1 2492/4885KDM4E 4833/4885HPGD 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.